Events
Dissertation: Jussi Lantto
Opponent: P0rofessor Hannu Kankaanranta,Universitry of Tampere
Dissertation: Ceren Pajanoja
Opponent: Professor Igor Adameyko, Karolinska Institutet, Sweden and Medical University Vienna, Austria
HiLIFE webinar / Viikki Monday Seminar. Avi Schroeder
Avi Schroeder is a Professor of Chemical Engineering at the Technion–Israel Institute of Technology, where he heads the Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies.
Dr. Schroeder conducted his PhD studies jointly at the Hebrew and Ben Gurion Universities, and postdoctoral studies at MIT under the guidance of Prof. Langer.
Avi has received more than 40 national and international recognitions, including being named a KAVLI Fellow and a fellow of the Royal Society of Chemistry, and winning the Intel Nanotechnology-, TEVA Pharmaceuticals-, and the Wolf Foundation Krill Awards. Avi is the author of over 80 papers and inventor of 23 patents. Avi is a co-founder of multiple startup companies based on these discoveries.
Dr. Schroeder is a former
member of the Israel’s Young National Academy of Sciences, is a current member
of Israel’s National Council for Civilian Research and Development, and is
currently serving as the President of the Controlled Release Society (CRS).
Presentation Abstract
Nanotechnology holds numerous potential benefits for treating disease, including the ability to transport complex molecular cargoes, including RNA and proteins, and targeting specific tissues, including the brain. Brain-targeted nanoparticles enhance the delivery of monoclonal antibodies (mAbs) across the blood-brain barrier (BBB) and into neurons, thereby allowing the intracellular and extracellular treatment of Parkinson’s disease. 100-nm BTL cross human BBB models intact and are taken up by primary neurons. Within neurons, SynO4 is released from the nanoparticles and bound to its target - alpha-synuclein (AS), thereby reducing AS aggregation, and enhancing neuronal viability. In vivo, intravenous administration results in a seven-fold increase in mAbs in brain cells, decreasing AS aggregation and neuroinflammation and improving mice's behavioral motor function and learning ability. Targeted nanotechnologies offer a valuable platform for drug delivery to treat brain neurodegeneration.
The evolution of drug delivery systems into synthetic cells, programmed nanoparticles with an autonomous syn-bio capacity to synthesize diagnostic and therapeutic proteins inside the body, and their promise for treating disease will be discussed.
Kliinisen kemian seminaarit
Marja Sarkola
Biostatistics drop-in workshop
Are you a researcher needing support with any statistical aspect of your work? The Biostatistics Consulting Service here at Meilahti Campus holds drop-in workshop sessions every other week to answer smaller questions about your analysis - solving a particular problem, how to get started, etc. We provide service in Finnish, English and Swedish.
The next workshop is on Wednesday 12th February, at 13:00-15:00 in Biomedicum 2B, in the Olohuone on floor 6. Come whenever you can. Note that you may end up waiting a while for your turn, especially early on in the session. We aim to spend no more than 15 minutes with each customer.
Bring:
· your computer
· your data
· your questions
and we biostatisticians will be on hand to help and guide.
Registration is not required, but you can help us prepare for your questions by filling in this form. The workshops are open to any researcher at the university's Medical Faculty, HUS or FIMM.
The following sessions are planned for 26th Feb, (N.B. 3-week interval!) 19th March, 2nd April, 16th April, 30th April, 14th May and 28th May.
For more in-depth questions, please book a one-on-one consultation session using this e-form where we will have time to go into more detail.
From the Biostatistics Team